|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Alanine aminotransferase measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases.
|
29403010 |
2018 |
|
Serum Alanine Aminotransferase Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases.
|
29403010 |
2018 |
|
Platelet mean volume determination (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Reticulocyte count (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
QRS complex feature
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
52 Genetic Loci Influencing Myocardial Mass.
|
27659466 |
2016 |
|
Malignant neoplasm of thyroid
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our aim was to establish a mouse model of thyroid-specific expression of STRN-ALK and to test whether this fusion drives the development of thyroid cancer with a propensity for dedifferentiation.
|
30125543 |
2018 |
|
Thyroid Neoplasm
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Transgenic mice with thyroid-specific expression of STRN-ALK developed poorly differentiated thyroid tumors by the age of 12 months in 22% of mice without goitrogen treatment and in 36% of mice with goitrogen treatment.
|
30125543 |
2018 |
|
Thyroid carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our aim was to establish a mouse model of thyroid-specific expression of STRN-ALK and to test whether this fusion drives the development of thyroid cancer with a propensity for dedifferentiation.
|
30125543 |
2018 |
|
Renal Cell Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Finally, ALK-rearrangement RCC seems to have 2 different clinical settings, one with sickle cell trait (VCL-ALK fusion) and the other without (other fusions such as TPM3-ALK, EML4-ALK, and STRN-ALK fusions).
|
28181950 |
2017 |
|
Renal Cell Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Here, we describe 2 cases of RCC harboring a novel striatin (STRN)-ALK fusion.
|
26848800 |
2016 |
|
Malignant neoplasm of thyroid
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that STRN-ALK fusion occurs in a subset of patients with highly aggressive types of thyroid cancer and provide initial evidence suggesting that it may represent a therapeutic target for these patients.
|
24613930 |
2014 |
|
Thyroid Neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that STRN-ALK fusion occurs in a subset of patients with highly aggressive types of thyroid cancer and provide initial evidence suggesting that it may represent a therapeutic target for these patients.
|
24613930 |
2014 |
|
Thyroid carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that STRN-ALK fusion occurs in a subset of patients with highly aggressive types of thyroid cancer and provide initial evidence suggesting that it may represent a therapeutic target for these patients.
|
24613930 |
2014 |
|
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Both SLMAP and STRN are linked to cardiac conditions, including heart failure, and their role in cardiomyocyte function was elucidated in our laboratory.
|
31233748 |
2019 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Both SLMAP and STRN are linked to cardiac conditions, including heart failure, and their role in cardiomyocyte function was elucidated in our laboratory.
|
31233748 |
2019 |
|
Adenomatous Polyposis Coli
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have previously shown that striatin colocalizes with the tumor suppressor protein adenomatous polyposis coli in the TJs of epithelial cells.
|
30592649 |
2019 |
|
Cardiomyopathies
|
0.010 |
Biomarker
|
group |
BEFREE |
Similarly, STRN is a dynamic protein that is also involved in cardiac E-C coupling and ICD-related cardiomyopathies.
|
31233748 |
2019 |
|
Anaplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our aim was to establish a mouse model of thyroid-specific expression of STRN-ALK and to test whether this fusion drives the development of thyroid cancer with a propensity for dedifferentiation.
|
30125543 |
2018 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
SG2NA was first discovered as nuclear autoantigen in lung and bladder cancer patient.
|
30132185 |
2018 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
SG2NA was first discovered as nuclear autoantigen in lung and bladder cancer patient.
|
30132185 |
2018 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Novel driver fusions such as POR-BRAF, as well as STRN-ALK fusions that have not been implicated in radiation-associated cancer before, were found.
|
29165687 |
2018 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We demonstrated that NAGLU-IKZF3, RNF121-FOLR2, and STRN-ALK had tumourigenic effects in CRC.
|
29955133 |
2018 |
|
Thyroid Nodule
|
0.010 |
Biomarker
|
disease |
BEFREE |
As <i>ETV6-NTRK3</i> and <i>STRN-ALK</i> are recurrent and not identified in benign lesions, they can certainly help with diagnosis of thyroid nodules.
|
29046324 |
2018 |